Nymox Provides New Update on Regulatory Activities
30 March 2021 - 12:20AM
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to
provide the latest update on the Company's regulatory filing
preparation activities. The Company expects to file for approval
for its first in class BPH treatment Fexapotide Triflutate, during
the summer of this year. Management will provide a firm exact date
for the filing in a subsequent disclosure. This communication of
the exact date for the filing will be announced by the Company
within the next 6 weeks. If there are any unexpected events that
delay that announcement, the Company will provide immediate
relevant updates.
Paul Averback MD, CEO of Nymox, said, "We are
very pleased to be able to provide a clear guidance on dates at the
above noted schedule within the next 6 weeks. We are grateful to
our strong supporters who have understood that the process is not
always conducive to fully predictable timelines. At this point
however we are confident that we will be providing very specific
details in that regard in the near future. Our product is capable
of producing major improvements in men's health and it is
remarkably safe and convenient to administer. We are working
diligently toward the goal of making it available to men throughout
the world."
Dr. Averback added, "The last major drug
innovations for BPH (alpha blockers and 5-ARIs) were first
introduced over 30 years ago. If our work was an easy task, others
would have accomplished this decades ago."
For more information please contact
info@nymox.com or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Nymox, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including statements regarding the need for new options to
treat BPH and prostate cancer, the potential of Fexapotide to treat
BPH and prostate cancer and the estimated timing of further
developments for Fexapotide. Such forward-looking statements
involve substantial risks and uncertainties that could cause our
clinical development program, future results, performance or
achievements to differ significantly from those expressed or
implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in
the clinical drug development process, including the regulatory
approval process, the timing of Nymox's regulatory filings, Nymox's
substantial dependence on Fexapotide, Nymox's commercialization
plans and efforts and other matters that could affect the
availability or commercial potential of Fexapotide. Nymox
undertakes no obligation to update or revise any forward looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of Nymox in general, see Nymox's current
and future reports filed with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 20-F for the year
ended December 31, 2020, and its Quarterly Reports.
For Further Information
Contact: Erik
Danielsen Nymox
Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From Apr 2024 to May 2024
Nymox Pharmaceutical (NASDAQ:NYMX)
Historical Stock Chart
From May 2023 to May 2024